Mankind Pharma Acquires Roche’s Rivotril Brand to Strengthen CNS Portfolio in India

Significant development for India’s pharmaceutical sector, Mankind Pharma Limited has acquired the rights to the well-known brand Rivotril from Roche for the Indian market. The agreement grants Mankind exclusive rights to manufacture, market, and distribute the drug across the country. However, the financial details of the transaction have not been disclosed.  

Rivotril, the innovator brand for clonazepam is a widely prescribed benzodiazepine used in the management of epilepsy, including myoclonic seizures, as well as certain neurological and psychiatric conditions. Over the years, the brand has earned strong recognition among healthcare professionals and is often regarded as a “textbook” drug due to its clinical reliability and long-standing presence.  

Strategic Expansion into CNS Therapies  

The acquisition aligns with Mankind Pharma’s strategy to expand its footprint in chronic and specialty therapy segments, particularly within the central nervous system (CNS) space. Headquartered in New Delhi, the company has established itself as a major player in affordable generic medicines and continues to diversify its portfolio through strategic acquisitions and in licensing agreements.  

With the addition of Rivotril, Mankind aims to strengthen its neurology portfolio and offer a more comprehensive range of treatments for epilepsy and related disorders. The move is also expected to enhance accessibility and affordability, as local manufacturing and distribution could reduce supply constraints and pricing pressures.  

Market Response and Industry Context  

Following the announcement, shares of Mankind Pharma rose by approximately 3%, reflecting positive investor sentiment and confidence in the strategic relevance of the deal.  

The acquisition also highlights a broader trend within the pharmaceutical industry, where multinational companies such as Roche are streamlining their portfolios by divesting mature brands in emerging markets. These brands are often transferred to domestic companies with stronger distribution networks and a deeper understanding of local market dynamics.  

Implications for Stakeholders  

For patients, the transition is expected to ensure continued availability of a trusted medication, potentially at improved price points. For healthcare professionals, the acquisition maintains continuity in prescribing practices, preserving confidence in a well established brand.  

From an industry perspective, the deal underscores the growing role of Indian pharmaceutical companies in acquiring and managing legacy brands. It reflects a shift toward higher-value segments, including chronic and specialty therapies, as domestic firms aim to move beyond traditional generics.  

Outlook  

While Mankind Pharma already has a presence in the CNS segment, this acquisition represents one of its most prominent moves in the space. Industry observers expect the company to invest further in brand development, awareness initiatives, and possibly new formulations or line extensions related to clonazepam.  

As India’s pharmaceutical market continues to evolve such strategic acquisitions are likely to play a key role in bridging global innovation with domestic accessibility.